Animal and Human Studies on Specialized Pro-Resolving Mediators in MS
Research indicates that specialized pro-resolving mediators (SPMs), such as resolvins, lipoxins, and maresins, can reduce neuroinflammation, prevent demyelination, and restore immune balance. Human studies show systemic deficiencies in lipid resolution pathways with increased pro-inflammatory eicosanoids.
- Most relevant to
- —
Why it matters
This knowledge might help in developing therapies that improve inflammation resolution in multiple sclerosis (MS), potentially aiding recovery and symptom management.
What this does not prove
Key questions remain about the causes of resolution failure, its varying dynamics at different disease stages, and the applicability of SPM interventions in human patients.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Other
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-07
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Neuroinflammation, Regeneration, Other
Original sources
- Primary evidenceResolution Failure in Multiple Sclerosis: Linking Lipid Mediators to Neuroinflammation and Disease Progression. ↗DOI: 10.1007/82_2026_357
Supporting passages (8)
study phaseThis chapter integrates current knowledge of MS pathogenesis, focusing on the central emerging concept that MS reflects a fundamental failure of inflammation resolution.
study designPreclinical studies demonstrate that SPMs such as resolvins, lipoxins, and maresins reduce neuroinflammation, prevent demyelination, and restore immune balance, while human metabolipidomic data reveal systemic deficiencies in pro-resolving lipid pathways alongside enrichment of pro-inflammatory eicosanoids.
subjectsThis framework unifies relapsing and progressive disease mechanisms and provides a rationale for therapeutic strategies aimed at restoring endogenous resolution pathways.
research categoriesThis chapter integrates current knowledge of MS pathogenesis, focusing on the central emerging concept that MS reflects a fundamental failure of inflammation resolution.
publication datePublication date: 2026-10-07
interventionSpecialized pro-resolving mediators (SPMs), which normally terminate inflammation and promote tissue repair, are consistently dysregulated in experimental and human MS.
findingsPreclinical studies demonstrate that SPMs such as resolvins, lipoxins, and maresins reduce neuroinflammation, prevent demyelination, and restore immune balance, while human metabolipidomic data reveal systemic deficiencies in pro-resolving lipid pathways alongside enrichment of pro-inflammatory eicosanoids.
limitationsNevertheless, key questions remain regarding the origin of resolution failure, its stage-specific dynamics, and the translational efficacy of SPM-based interventions in humans.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.